![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
First study of repeat dose co-administration of GSK1265744 and TMC278 long-acting parenteral nanosuspensions: pharmacokinetics, safety, and tolerability in healthy adults
|
|
|
Reported by Jules Levin
IAS 2013 Kuala Lumpur June 30-July 3
W. Spreen1, P. Williams2, D. Margolis1, S. Ford1, H. Crauwels2,
Y. Lou1, E. Gould1, M. Stevens2, S. Piscitelli1
1GlaxoSmithKline, Infectious Diseases Research & Development, Research Triangle Park, United States, 2Janssen Infectious Diseases BVBA, Beerse, Belgium
![IAS1.gif](../images/070513/070513-8/IAS1.gif)
![IAS2.gif](../images/070513/070513-8/IAS2.gif)
![IAS3.gif](../images/070513/070513-8/IAS3.gif)
![IAS4.gif](../images/070513/070513-8/IAS4.gif)
![IAS5.gif](../images/070513/070513-8/IAS5.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|